Correlation Between Precision BioSciences and Elicio Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Precision BioSciences and Elicio Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Precision BioSciences and Elicio Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Precision BioSciences and Elicio Therapeutics, you can compare the effects of market volatilities on Precision BioSciences and Elicio Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Precision BioSciences with a short position of Elicio Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Precision BioSciences and Elicio Therapeutics.

Diversification Opportunities for Precision BioSciences and Elicio Therapeutics

-0.68
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Precision and Elicio is -0.68. Overlapping area represents the amount of risk that can be diversified away by holding Precision BioSciences and Elicio Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Elicio Therapeutics and Precision BioSciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Precision BioSciences are associated (or correlated) with Elicio Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Elicio Therapeutics has no effect on the direction of Precision BioSciences i.e., Precision BioSciences and Elicio Therapeutics go up and down completely randomly.

Pair Corralation between Precision BioSciences and Elicio Therapeutics

Given the investment horizon of 90 days Precision BioSciences is expected to under-perform the Elicio Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Precision BioSciences is 1.7 times less risky than Elicio Therapeutics. The stock trades about -0.2 of its potential returns per unit of risk. The Elicio Therapeutics is currently generating about 0.08 of returns per unit of risk over similar time horizon. If you would invest  434.00  in Elicio Therapeutics on August 23, 2024 and sell it today you would earn a total of  78.00  from holding Elicio Therapeutics or generate 17.97% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Precision BioSciences  vs.  Elicio Therapeutics

 Performance 
       Timeline  
Precision BioSciences 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Precision BioSciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's forward indicators remain quite persistent which may send shares a bit higher in December 2024. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.
Elicio Therapeutics 

Risk-Adjusted Performance

5 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Elicio Therapeutics are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Elicio Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Precision BioSciences and Elicio Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Precision BioSciences and Elicio Therapeutics

The main advantage of trading using opposite Precision BioSciences and Elicio Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Precision BioSciences position performs unexpectedly, Elicio Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Elicio Therapeutics will offset losses from the drop in Elicio Therapeutics' long position.
The idea behind Precision BioSciences and Elicio Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.

Other Complementary Tools

Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing